Anthropic PBC is moving aggressively into the life sciences sector with the launch of Claude Science, a new software platform aimed at streamlining repetitive research work and enabling scientists to focus on higher-value intellectual tasks. The AI-powered tool, which became available to paid subscribers on June 30, represents the company's latest push to expand artificial intelligence applications beyond consumer and general business use into specialized professional domains where technical expertise traditionally commands premium compensation.
The platform consolidates access to over 60 scientific databases and computational tools that researchers currently navigate separately, allowing scientists to perform complex multi-stage tasks through natural language queries. Rather than manually switching between databases to predict protein structures, retrieve chemical compound information, or cross-reference biological data, researchers can now issue plain-English instructions and receive integrated answers. This architectural approach reflects a broader strategy in the AI industry to reduce friction in professional workflows by eliminating the need for users to understand multiple specialized interfaces and data formats.
Anthropicannounced the launch at a San Francisco event where Chief Executive Officer Dario Amodei discussed the company's ambitions alongside Vas Narasimhan, CEO of pharmaceutical giant Novartis AG and a board member at Anthropic, and Chris Boerner, CEO of Bristol-Myers Squibb. The convening of major pharma executives underscores how seriously the industry is taking AI-assisted drug discovery, even as questions persist about whether artificial intelligence can genuinely accelerate the lengthy, expensive process of bringing new medicines to market.
Beyond the software release, Anthropic disclosed it is establishing its own in-house preclinical drug discovery programmes, marking a significant shift from being purely a technology vendor to becoming an active participant in pharmaceutical research. Eric Kauderer-Abrams, the company's head of life sciences, indicated that these internal efforts will target therapeutic areas that traditional pharmaceutical and biotech companies have deemed commercially unattractive—a strategy that could address neglected diseases affecting populations in developing markets, including Southeast Asia, where profit margins are limited but medical need is acute.
The timing of these announcements reflects Anthropic's wider competitive positioning. The company, currently valued at US$965 billion (RM3.94 trillion), is racing against OpenAI and other AI developers to demonstrate that artificial intelligence delivers concrete business value across multiple sectors. This race toward diverse applications is partly driven by investor expectations and the company's reported plans to pursue an initial public offering as soon as autumn, requiring a narrative that extends beyond conversational AI chatbots into vertically integrated solutions that justify extraordinary valuations.
Anthropichas already begun to reshape professional services. In February, the company introduced Claude Cowork, a tool for automating legal work such as contract review and legal memoranda. That announcement triggered stock market volatility, with indices dropping roughly US$1 trillion (RM4.08 trillion) as investors digested implications for white-collar employment and professional service firms. The reaction illustrated how deeply markets worry that AI commoditizes high-skill professional labor, a concern that resonates across Malaysia and the region where knowledge work and professional services represent important economic sectors.
Claude Science builds on existing models, particularly Opus 4.8, which Anthropic released in May. A critical design feature addresses the scientific community's requirement for reproducibility and verification: the tool provides traceable documentation showing how it reached conclusions, and any images generated include methodological details. This commitment to transparency represents a response to legitimate concerns within the scientific community about AI hallucination and false confidence in outputs, particularly in high-stakes domains like drug discovery where errors could waste research resources or, worse, contribute to ineffective or harmful treatments.
Dario Amodei framed expectations cautiously, stating he hopes to demonstrate "some success" within one year in identifying new drug targets using AI. His restrained language suggests awareness that pharmaceutical development timelines are measured in years and decades, and that bold proclamations about AI without corresponding clinical results risk damaging credibility. Narasimhan echoed this sentiment at the event, remarking that "we've made a lot of bold proclamations, and now I think we need to actually show for patients that we actually are delivering real results." This acknowledgement from a major pharma chief executive signals that the industry recognizes a credibility gap between AI enthusiasm and tangible medical breakthroughs.
Regulatory considerations loom large. Narasimhan called for appropriate AI regulation to be established proactively, cautioning that waiting for a crisis to catalyze regulatory frameworks is suboptimal governance. His comments align with broader discussions across the Asia-Pacific region about AI oversight, where countries including Malaysia, Singapore, and others are developing regulatory frameworks. The integration of advanced AI systems into pharmaceutical development raises questions about safety standards, export controls, and how different nations coordinate governance of dual-use technology.
Anthropichas also been navigating geopolitical constraints. The company recently disabled access to its most advanced models, Fable 5 and Mythos 5, following a Trump administration order restricting technology transfer to foreign nationals. On June 26, Anthropic obtained approval to partially restore access to Mythos 5 after addressing national security concerns, though Fable 5 access remains suspended. These restrictions illustrate how AI development is increasingly subject to export control regimes similar to historical restrictions on semiconductor and defense technology, with significant implications for international scientific collaboration and for researchers and companies operating across borders in Southeast Asia.
For Malaysian scientists and research institutions, Claude Science presents both opportunity and challenge. The platform could enable local research teams to access computational capabilities and databases at scale, potentially leveling the playing field against better-resourced institutions in developed economies. Simultaneously, the integration of such tools into research workflows creates dependencies on foreign technology platforms and raises questions about data sovereignty, intellectual property rights in collaborations involving AI, and the long-term economics of subscription-based research infrastructure. As the region's scientific capabilities deepen, these considerations will shape how countries position themselves in the global AI-augmented research ecosystem.
